Biopharma Co. Accused Of Lying To Investors About FDA Hold
By Emilie Ruscoe ( August 8, 2022, 8:15 PM EDT) -- An investor in biotherapeutics company Kiromic BioPharma Inc. has launched a proposed class action accusing the company and its leadership of touting prospects for two drug candidates ahead of a 2021 public offering despite the fact that the U.S. Food and Drug Administration had hit pause on clinical trials for both therapeutics....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.